Abstract: A process, for the quantitative analysis by optical emission spectroscopy of a plasma induced by a laser beam of at least one target included in a biochip, involves the use of an adjuvant allowing the formation of a dry matrix capable of being ablated simultaneously with the at least one target, the dry matrix being configured to improve the analytical properties of plasma, the adjuvant having an emission spectrum whose lines have wavelengths distinct from the wavelengths of the spectral lines used for the quantitative analysis of said at least one target.

Abstract: The invention relates to a method for evaluating, via biodosimetry, the irradiation dose received by a person subjected to ionizing radiation. Said method comprises: a) sampling, in at least one area of the body of the person, the follicles or bulbs of head and/or body hair of the person; b) extracting proteins from cells of said sampled hair bulbs or follicles, wherein said proteins, including proteins from the ATM system, are subjected to phosphorylation and/or acetylation induced by ionizing radiation; and c) analyzing at least two types of extracted proteins and interpreting the analysis results in order to determine the irradiation dose in the or each sampling area.

Abstract: A process, for the quantitative analysis by optical emission spectroscopy of a plasma induced by a laser beam of at least one target included in a biochip, involves the use of an adjuvant allowing the formation of a dry matrix capable of being ablated simultaneously with the at least one target, the dry matrix being configured to improve the analytical properties of plasma, the adjuvant having an emission spectrum whose lines have wavelengths distinct from the wavelengths of the spectral lines used for the quantitative analysis of said at least one target.

Abstract: Novel chimeric molecules, termed “half-antibodies”, which are capable of self-assembling to form an epitope recognition site. Using these half-antibodies or a vesicle, a viral particle, a composition or a kit thereof, for therapeutic applications, such as the prevention or treatment of cancers, genetic diseases, infectious diseases, and for in vitro diagnostic applications and detecting biological molecules. The half-antibodies include at least two chimeric molecules A and B, each has a polypeptide domain characteristic of a variable domain of a heavy chain or of a light chain of an antibody, and a nucleotide domain, the nucleotide domain of A and that of B being capable of pairing into a double stranded structure. Biologically active nucleic sequences can be grafted onto these chimeric molecules to prevent the expression of target genes in the interior of a human or non-human mammalian cell.